Despite hitting the market more than a year ago with steep discounts, biosimilars for AbbVie’s blockbuster arthritis treatment Humira (adalimumab) have managed to take only 4% of the market share away from the branded reference product, according to the latest quarterly report from Samsung Bioepis.
Tag Archive for: AbbVie
This transaction is the latest to highlight Big Pharma’s growing interest in developing novel targets for inflammation and immunology (I&I) treatments, as well as the potential for cutting-edge computational drug development.
AbbVie Inc. and Landos Biopharma, Inc. today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
The full approval makes Elahere the “first and only antibody-drug conjugate (ADC) approved in the U.S. for” ovarian cancer, a “difficult-to-treat malignancy,” AbbVie CMO of global therapeutics Roopal Thakkar, said in a statement.
AbbVie on Wednesday entered into a strategic partnership with OSE Immunotherapeutics to advance the French biotech’s early-stage monoclonal antibody OSE-230 as a treatment for chronic and severe inflammation.
Yesterday the company stated that Chief Operating Officer Robert Michael would succeed Richard Gonzalez to become the second-ever CEO of the drugmaker on July 1.
The Chicago-based drugmaker has been counting on revenues from its newer immunology medicines to help make up for declining sales of its blockbuster arthritis drug Humira.
Despite offering discounts that reach as high as 85%, Humira biosimilars are finding it difficult to take market share away from the AbbVie blockbuster, according to a new report from Samsung Bioepis.
Botox sales, especially for aesthetic use, have been under pressure over the last few quarters due to economic uncertainties. Investors have also been concerned about potential market share losses to new entrants.
Yesterday’s dual agreements with Umoja continues AbbVie’s dealmaking spree in late 2023, which saw the pharma ink two multibillion-dollar agreements. The first was with ImmunoGen and its deep portfolio of antibody-drug conjugates (ADC), which AbbVie bought for $10.1 billion.